Back to News
Market Impact: 0.2
PharmAla & Rua Bioscience Partner To Supply GMP-Grade MDMA For PTSD In New Zealand
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
PharmAla Biotech Holdings and Rua Bioscience signed a distribution and licensing agreement for the supply of pharmaceutical-grade MDMA in New Zealand. The announcement did not disclose financial terms or supply volumes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements
- AI Tools for Independent Research Firms: A Publishing System